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A critical factor in edible plant-derived vaccine development is adequate expression of the exogenous antigens in transgenic plants. We
synthesized a codon-optimized gene (sVP6) encoding the VP6 protein of human group A rotavirus and inserted it into the alfalfa genome
using agrobacterium-mediated transformation. As much as 0.28% of the total soluble protein of the pBsVP6-transgenic alfalfa was sVP6.
Female BALB/c mice were gavaged weekly with 10 mg of transgenic alfalfa extract containing 24 Ag of sVP6 protein and 10 Ag of CpG-rich
oligodeoxynucleotides as mucosal adjuvant. Immunized mice developed high titers of anti-VP6 serum IgG and mucosal IgA. Offspring of
immunized dams developed less severe diarrhea after challenge with simian rotavirus SA-11, indicating that antibodies generated in the dams
provided passive heterotypic protection to the pups. These results suggest that oral immunization with pBsVP6-transgenic alfalfa provides a
potential means of protecting children and young animals from severe acute rotavirus-induced diarrhea.
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Plants have considerable potential for the production of
biopharmaceutical proteins because they are easily trans-
formed and provide an inexpensive source of protein. The
production of a subunit vaccine in transgenic plants was first
reported by Mason et al. (1992), who integrated a DNA
fragment encoding the hepatitis B surface antigen (HBsAg)
into the genome of tobacco plants using agrobacterium-
mediated transformation. In this system, the expressed
HBsAg retains the capacity to self-assemble into virus-like
particles, which is a much more immunogenic form of the
antigen than the peptide alone (Mason et al., 1992). Since
then, several groups have used plants to express a variety of
bacterial and viral antigens. Escherichia coli heat labile B
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capsid protein, respiratory syncytial virus F protein, and
measles virus hemagglutinin have been successfully
expressed in plants and delivered orally to animals or
humans to determine their respective immunogenicities
(Arakawa et al., 1998; Huang et al., 2001; Mason et al.,
1998; Sandhu et al., 2000; Tacket, 2000; Wigdorovitz et al.,
1999).
Tobacco and potato plants were employed as test systems
in early plant-derived vaccine research because of the ease
of transformation and regeneration in these models. How-
ever, tobacco leaves are inedible, making protein extraction
a necessary step prior to the administration of the product as
an oral vaccine. Potatoes are not normally eaten raw, but
cooking would denature the transgenic proteins and reduce
the immunogenicity. Other candidate host plants such as
tomato, banana, corn, lettuce, and alfalfa have been used for
plant-derived vaccine production (Streatfield et al., 2003;
Tacket and Mason, 1999; Wigdorovitz et al., 1999). Alfalfa
(Medicago sativa L.) is a perennial crop that continues to
produce for up to 5 years after establishment. The plant has05) 153 – 163
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stem cuttings to produce large clonal populations within a
limited time period. The low levels of secondary metabolites
and high protein content in the leaves of alfalfa make it a
good bioreactor for the production of recombinant proteins
(Erickson et al., 2002). Dus Santos et al. (2002) reported a
simple method to obtain transgenic alfalfa expressing high
levels of foreign epitopes (VP135–160) from FMDV. The
FMDVepitope expressed in plants was highly immunogenic
in mice, which developed a strong anti-FMDV antibody
after immunization.
Rotaviruses are the most important causes of viral
gastroenteritis in young children and animals worldwide.
Most children are infected with rotavirus at least once before
they are 3 years old, and approximately 6% of deaths among
children in developing countries are attributable to rotavirus
infection (Dodet et al., 1997). Thus, there is an urgent need
to develop safe and effective vaccines against rotavirus
infection. The nucleocapsids of the group A rotaviruses are
composed of three concentric layers of proteins enclosing 11
segments of double-stranded RNA. The outer capsid layer is
composed of two proteins, VP7 and VP4, which are the only
targets of neutralizing antibodies and define the G and P
serotypes, respectively, of viral isolates (Ramig, 1997). The
innermost capsid layer consists of protein VP2, whereas the
intermediate layer is formed by protein VP6, which
constitutes approximately 51% of the virion by weight.
Antibodies against VP6 are highly cross-reactive among all
group A rotaviruses; therefore, VP6-based vaccines could
potentially provide heterotypic protection (Prasad and Chiu,
1994). Although anti-VP6 antibodies do not exhibit virus
neutralizing activity, anti-VP6 secretory IgA has a critical
role in protective immunity against rotavirus infection
(Burns et al., 1996). Anti-VP6 IgA confers protection in
vivo by inhibiting viral transcription at the start of the
intracellular phase of the viral replication cycle (Feng et al.,
2002). In addition, immunization with VP6 may prime the
immune system for enhanced production of neutralizing
antibodies against the external proteins (VP7 and VP4) upon
challenge with homotypic or heterotypic viruses (Esquivel
et al., 2000).
Based on these and other results, several candidate VP6-
based vaccines have been developed. Immunization with
VP6 DNA or virus-like particles composed of VP2 and VP6
efficiently protected mice from rotavirus infection (Conner
et al., 1996; Yang et al., 2001). The VP6 genes of bovine or
murine rotaviruses were expressed in transgenic potatoes
after Agrobacterium tumefaciens-mediated transformation
(Matsumura et al., 2002; Yu and Langridge, 2003).
However, the amount of VP6 protein produced in transgenic
potato tubers is low, being limited to approximately 0.002%
to 0.1% of the total soluble protein (Matsumura et al., 2002;
Yu and Langridge, 2003). The VP6 gene was also expressed
in Nicotiana benthamiana from potato virus X vectors, and
the expressed protein was shown to self-assemble into virus-
like particles (O’Brien et al., 2000). Although some of theseoral vaccine candidates elicited specific anti-VP6 serum IgG
and mucosal IgA antibodies (Matsumura et al., 2002; Yu
and Langridge, 2003; Garcı´a-Dı´az et al., 2004), few data on
challenge experiments are available. However, the low
levels of antigenic proteins in the plant materials suggest
that increased VP6 expression in transgenic plants will be a
key factor in oral vaccine development.
Here, we report that M. sativa transformed with the
pBsVP6 vector expressed a high level of human group A
rotavirus sVP6 protein. Immunization with extracts of the
transgenic alfalfa leaves elicited an efficient immune
response in mice that provided passive protection against
infection with simian rotavirus SA-11 in neonatal mice born
to immunized dams.Results
A codon-optimized sVP6 gene has been synthesized
To optimize the coding sequence of the VP6 gene
from human group A rotavirus (GenBank accession
no.AF260931) for expression in alfalfa, the 1194-nucleotide
coding sequence was modified to yield a new sequence,
sVP6, in which a number of codons were altered to match
the codon usage preferences of dicots. The GC content of
the gene was increased from 35% to 44%, which closely
approximated that of highly expressed dicot genes. In
addition, four ATTTA motifs, six potential polyadenylation
signal sequences, and one potential termination site for
RNA polymerase II were eliminated to permit transcription
of intact, mature, and translatable mRNA. The amino acid
sequence encoded by the modified sVP6 was identical to
that of the original VP6 gene to ensure retention of the
antigenicity of the transgenically expressed protein. The
nucleotide sequence of the sVP6 gene (GenBank accession
no. AY803761) was 87.94% homologous to the original
VP6 gene.
The structure of the sVP6 protein is similar to the native
VP6
SDS-polyacrylamide gel electrophoresis (PAGE) analy-
sis demonstrated that glutathione S-transferase (GST) fusion
proteins of sVP6 and VP6 (GST-sVP6 and GST-VP6)
expressed in E. coli BL21 were of equal size (65 kDa). The
sVP6 protein purified by GST affinity chromatography
thrombin, and fast protein liquid chromatography (FPLC)
had a relative molecular weight of 42 kDa under denaturing
conditions (treated samples for 5 min at 100 -C, sample
buffer containing h-mercaptoethanol). Both sVP6 and
native VP6 proteins were monomer (42 kDa) under
denaturing condition, while existed as trimers (¨130 kDa)
under nondenaturing conditions (treated samples for 30 min
at 37 -C, sample buffer without h-mercaptoethanol). West-
ern blot analysis further confirmed that the sVP6 protein and
Fig. 1. Detection of recombined sVP6 protein by Western blotting with
rabbit anti-VP6 antibodies. Samples were treated for 5 min at 100 -C under
denaturing conditions (lanes 2 and 4) or for 30 min at 37 -C under
nondenaturing conditions (lanes 1 and 3), then subjected to SDS-PAGE and
blotted onto a nitrocellulose membrane. After blocking, the membrane was
reacted with rabbit anti-VP6 polyclonal antibody, then with alkaline
phosphatase-conjugated goat anti-rabbit IgG. Finally, the membrane was
developed by NBT/BCIP. Lanes 1 and 2: purified sVP6 protein expressed
in E. coli; lanes 3 and 4: purified native VP6 protein (control) expressed in
E. coli; M: protein molecular weight markers.
Fig. 3. (A) Identification of the integration of sVP6 gene into plant genome
by Southern blotting. Lane 1, SacI and HindIII double-digested pBsVP6
(2.4 kb); lane 2, HindIII-excised pBsVP6 plasmid (positive control
14.4 kb); lane 3, HindIII-excised untransformed plant genomic DNA
(negative control); lane 4, SacI-excised untransformed plant genomic DNA
(negative control); lanes 5, 7, 9, and 11, transformed plant genomic DNA
samples digested with HindIII; lanes 6, 8, 10, and 12, transformed plant
genomic DNA samples digested with SacI. (B) Detection of sVP6 mRNA
by RT-PCR. The sVP6-specific RT-PCR products amplified from: lanes 1–
4, total RNA extracted from pBsVP6-transformed alfalfa; lane 5, total RNA
from untransformed alfalfa (negative control). Lane 6, PCR products from
pBsVP6 plasmid DNA (positive control); M, 1 kb molecular weight ladder.
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antibodies (Fig. 1). These results indicated that the structure
of the sVP6 protein is similar to that of native VP6.
Construction of the transformation vector pBsVP6
The transformation vector pBsVP6 contains the cauli-
flower mosaic virus (CaMV) 35S promoter with dual
enhancers to drive transcription of the sVP6 gene and the
nopaline synthase (nos) terminator to stop transcription.
The 5V-untranslated region of the tobacco etch virus
(TEV) serves as a translation enhancer, and a Kozak
sequence is present to optimize translation. A sequence
encoding the endoplasmic reticulum retention signal
SEKDEL was fused to the 3V end of sVP6 gene to
ensure intracellular compartmentalization of the fusion
protein. pBsVP6 also contains the kanamycin resistance
marker (NPT II) which permits the selection of trans-
formed plants (Fig. 2).
Genetic analysis of transformed alfalfa
Agrobacterium tumefaciens LBA4404 was transformed
with pBsVP6 and used for alfalfa transformation. Ten toFig. 2. Construction of the plant transformation vector pBsVP6 for the expression
the alfalfa genome contained two cassettes: the NPT II cassette, which confers
cassette. The 35S promoter with dual enhancers from cauliflower mosaic virus was
stop transcription. The 5V-untranslated region of the tobacco etch virus (TEV) serve
translation. The SEKDEL retention signal was fused to the 3V end of the sVP6 g12 weeks after transformation, 78 kanamycin-resistant
plants were obtained. To confirm that the sVP6 gene
was stably integrated into the chromosomal DNA of the
transformed alfalfa, genomic DNA and total RNA were
extracted from young leaves of transgenic plants and
analyzed by Southern blotting and RT-PCR, respectively.
Genomic DNA samples and recombinant pBsVP6 plasmid
were digested with SacI and HindIII restriction endonu-
cleases outside the target gene. Southern blot showed that
the profiles of digested products (band size) are different
among transgenic plants, and between SacI and HindIII
double-digested pBsVP6 and HindIII-excised pBsVP6
plasmid; whereas no bands were detected in the untrans-
formed plants. These data confirmed the integration of
sVP6 gene into plant genome, but not the contamination of
plant with A. tumefaciens (Fig. 3A). Transcription of theof the human rotavirus sVP6 gene in alfalfa. The DNA region inserted into
kanamycin resistance to plants, and the human rotavirus sVP6 expression
used to drive transcription, and the nopaline synthase terminator was used to
d as a translation enhancer, and a Kozak sequence was included to optimize
ene.
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generation of a single 1.2-kb product in tested lines after
RT-PCR, whereas no specific products were detected in the
wild-type plants (Fig. 3B). These results demonstrated that
the sVP6 gene was integrated into the nuclear genome and
expressed in transgenic alfalfa.
Expression of sVP6 protein in transgenic alfalfa
Total soluble protein (TSP) was extracted from trans-
formed alfalfa leaves to examine the expression of sVP6
protein. Western blotting showed that recombinant sVP6Fig. 4. (A) Western blot analysis of sVP6 protein expression in the leaves of pBsV
coli (positive control); lanes 2 and 3, pBsVP6-transformed plant leaves; lane 4
markers. (B) Quantitation of VP6 protein expressed in transgenic alfalfa leaves by
individual pBsVP6-transformed alfalfa plants. (C) Western blotting analysis protein
pBsVP6-transformed plant leaves (T0 generation, positive control); lane 2, wild-ty
pBsVP6-transformed plant leaves; M, protein molecular weight markers.protein (¨42 kDa) was produced in the transformed plants
and in recombined E. coli, whereas no sVP6 protein was
detected in the untransformed plants (Fig. 4A). The
quantification of sVP6 by sandwich ELISA showed that
0.06 to 0.28% of the TSP was sVP6; 18 transformed plants
expressed sVP6 protein in the range of 7.08 to 33.04 Ag/g of
fresh leaf weight (Fig. 4B). Western blotting using rabbit
anti-rotavirus VP6 serum further confirmed that sVP6
protein (42 kDa) was stably expressed in the first transgenic
(T1) generation of alfalfa as in T0 generations (Fig. 4C).
These results suggested that alfalfa is a promising system for
vaccine production.P6-transformed alfalfa. Lane 1, recombinant sVP6 protein expressed in E.
, wild-type alfalfa leaves (negative control); M, protein molecular weight
ELISA. Lane 1, untransformed alfalfa leaves; lanes 2–19, leaf samples from
s extracted from the T1 generation of the original transformed lines. Lane 1,
pe alfalfa leaves (negative control); lanes 3–8, T1 generation of the original
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pBsVP6-transgenic alfalfa leaves
To test the immunogenicity of sVP6 from transgenic
plant, six of the transgenic plants (Fig. 4B lanes 4, 5, 8, 14,
15 and 16) that expressed high levels of sVP6 protein were
grown in a greenhouse and propagated by stem cuttings.
Mice were gavaged on days 0, 7, 14, and 21 with 10 Ag of
oligodeoxynucleotides (ODN) containing immunostimula-
tory CpG motifs as a mucosal adjuvant and with 10 mg of
TSP extracted from the transgenic or control untransformed
plants, or with 24 Ag of recombinant sVP6 purified from E.
coli. As shown in Fig. 5A, mice gavaged with transgenic
TSP containing 24 Ag of sVP6 protein developed specific
anti-VP6 IgG with ELISA titers between 1:6,000 and
1:9,600. These titers were somewhat higher than those
elicited in mice immunized with sVP6 from E. coli, which
ranged from 1:4,800 to 1:7,200. The ELISA titers of
mucosal IgA in the saliva, feces, and homogenized small
intestines of mice immunized with transgenic alfalfa extractFig. 5. Anti-VP6 antibody titers determined by ELISA in mice after oral immuniz
(A) sVP6-specific serum IgG at 36 d after the first immunization. (B) Levels of IgA
saliva (C) and feces (D) were determined at weekly intervals for 4 weeks after the f
CpG; Group 2, 10 mg of TSP from transgenic alfalfa containing 24 Ag of sVP6 p
E. coli + 10 Ag of CpG.were also determined. The titers of anti-VP6 IgA found in
the saliva (Fig. 5C) and feces (Fig. 5D) were lower than
those found in the small intestine homogenate (Fig. 5B),
which ranged from 1:320 to 1:640. Mice gavaged with wild-
type alfalfa extract did not produce anti-VP6 antibodies.
The specificity of the anti-sVP6 antibody produced by
the immunized mice was further confirmed by Western
blotting using both purified sVP6 and rotavirus particles.
The sera from the mice immunized with pBsVP6-trans-
formed plant extract specifically recognized both sVP6
protein and native VP6 from rotavirus particles, whereas the
sera from animals immunized with untransformed alfalfa
did not show reactivity to sVP6 or native rotavirus particles
(Fig. 6).
Rotavirus challenge experiments
As mice are susceptible to rotavirus-induced diarrhea
only during the first 15 days of life, 5-day-old pups born to
immunized dams were challenged with 20DD50 simianation with wild-type or transgenic alfalfa or with sVP6 expressed in E. coli.
in the small intestine at 60 d after the first immunization. Levels of IgA in
irst immunization. Group 1, 10 mg of TSP from wild type alfalfa + 10 Ag of
rotein + 10 Ag of CpG; Group 3, 24 Ag of recombinant VP6 purified from
Fig. 6. The specificity of the antibodies from mice immunized with leaf
extracts from pBsVP6-transformed alfalfa as detected by Western blotting.
Several pools of sera from mice immunized with pBsVP6-transformed
plants (lanes 1–6) or with wild-type plants (lanes 7–8) were analyzed
using purified sVP6 protein (lanes 2, 4, 6, and 8) and rotavirus particles
(lanes 1, 3, 5, and 7) as antigens. M, protein molecular weight markers.
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rotavirus-induced diarrhea. The first group was consisted of
30 pups bred by 10 wild-type-alfalfa -immunized female
mice, the second group was consisted of 32 pups bred by 10
transgenic-alfalfa-immunized female mice, and the third
group was consisted of 24 pups bred by 10 recombinant-
sVP6-protein-immunized female mice. After challenge, the
anus of each pup was checked three times per day. The anus
of diarrheic mice was reddish and adhered with plenty of
feces, and the diarrheic symptomatic difference between
normal and diarrheic mice was obvious. Diarrhea symptom
of infected mice had been continuously observed for 10
days, and the intensity of diarrhea were determined
according to the color of anus and the amount of adhered
feces.
The proportion of pups with diarrhea symptoms, the
duration of diarrhea and the intensity of diarrhea were
significantly reduced in the offspring of mice immunized
with the transgenic alfalfa. Complete resolution of diarrheaFig. 7. Protection against rotavirus infection in passively immunized murine pups.
of simian rotavirus SA-11. The diarrhea symptoms and intensity of diarrhea we
diarrhea symptoms was calculated. The number of pups that developed diarrhea co
each column. Group 1: 30 pups bred by 10 untransgenic-alfalfa-immunized fema
mice. Group 3: 24 pups bred by 10 recombinant-sVP6-protein-immunized femalesymptoms occurred 5 days after virus challenge in pups
from transgenic-alfalfa-immunized female mice (Fig. 7).
These results suggested that the anti-VP6 antibodies
generated in orally immunized female mice were passively
transferred to the pups and provided heterotypic protection,
indicating that a plant-derived sVP6-based oral vaccine
could efficiently protect young animals and children from
severe acute diarrhea caused by human group A rotaviruses.Discussion
Rotaviruses are the leading cause of severe gastroenteritis
and dehydrating diarrhea in young children and animals
worldwide. Many newborn animals are susceptible to
rotavirus-induced diarrhea only during the first weeks of
life, making it difficult to actively immunize the animals
before exposure to the pathogen. As female mice are able to
passively transfer antibodies to their pups, we challenged
pups born to immunized dams with rotaviruses to study the
protection provided by immunization with transgenic alfalfa
expressing VP6. The rotavirus outer capsid proteins VP4
and VP7 have long been considered the targets for
protective immunity in vaccine development, as VP4 and
VP7 determine the virus serotype and mediate neutraliza-
tion. However, several studies have suggested that the levels
of the neutralizing antibody response do not always
correlate with protection (Ward et al., 1992a, 1992b).
Non-neutralizing IgA monoclonal antibodies directed
against the intermediate capsid protein VP6 can mediate
immunity against rotaviruses in vivo (Franco and Green-
berg, 1999; Feng et al., 2002). The induction of efficient
protection against rotavirus correlated with the level ofOn the fifth day post parturition, mouse pups were challenged with 20 DD50
re observed at least 10 days after challenge. The percentage of pups with
mparison to the total number of pups in each group is indicated on the top of
le mice. Group 2: 32 pups bred by 10 transgenic-alfalfa-immunized female
mice.
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level of rotavirus-specific serum IgG (Franco and Green-
berg, 1999). The intestinal IgA response in T cell-deficient
mice was roughly one-tenth that of immunocompetent mice
and was directed exclusively against VP6 (Franco and
Greenberg, 1999). Colostral antibodies produced in female
mice immunized with rotavirus VP4 or VP7 have been
reported to confer passive protection to their newborn
offspring (Kim et al., 2002; Wigdorovitz et al., 2004). No
successful passive immunization using VP6-based vaccines
has previously been reported. In this study, the severity and
duration of diarrhea induced by challenge with simian
rotavirus SA-11 were reduced significantly in passively
immunized pups, indicating that anti-VP6 antibodies gen-
erated in orally immunized female mice can be transferred
to their offspring.
The mucosal surfaces of the gastrointestinal, genito-
urinary, and respiratory tracts are the primary entry sites of
most pathogens. The induction of effective mucosal
immunity could greatly reduce the rates of infection and
morbidity. Thus, mucosal immunization, especially by the
oral route, has recently attracted much interest. The
expression of viral and bacterial antigens in plants has
opened up a new avenue for oral vaccine development.
Compared with the traditional routes of immunization, the
delivery of antigens produced in transgenic plants by the
oral route can potentially elicit production of effective levels
of local secretory IgA, which is the hallmark of mucosal
immunity. IgA is thought to protect the host against
pathogens that infect mucosal surfaces and those that cause
systemic disease after entry via a mucosal surface (Lamm,
1997). Oral vaccines have been proposed as particularly
suited for use in developing countries because of the ease of
production, handling, and administration, without risk of
needle-stick injury or cross-contamination. Rotavirus-spe-
cific IgA production has been demonstrated in the Peyer’s
patches and cells from mesenteric lymph nodes cultured in
vitro after intranasal and oral administration of a VP6 DNA
vaccine (Garcı´a-Dı´az et al., 2004). It has been previously
suggested that the expression of antigens in plants could
provide ‘‘bio-encapsulation’’ for the antigens and protect
them from degradation in the digestive tract until the plant
cells are degraded near the Peyer’s patches, which function
as effector sites for the initiation of mucosal immunity
(Kong et al., 2001). It is also possible that proteins or
secondary metabolites (e.g. polyphenolics) from plant cells
may associate with HBsAg and account for its protection in
the gastrointestinal tract (Kong et al., 2001). Basing on our
data (Fig. 5), we propose the possible mechanism of uptake
of VP6 protein expressed in transgenic alfalfa into intestine
is similar to that of HBsAg as described above. Bio-
encapsulation of VP6 antigens made in transgenic plants
may result in the induction of significant mucosal immune
responses that are otherwise difficult to achieve.
The previously reported levels of antigenic proteins
expressed in transgenic plants are as low as 0.01% and donot exceed 0.40% of the total soluble protein. Although the
recombinant target proteins expressed in chloroplast-trans-
formed tobacco and tomato plants can be up to 46% of
total soluble protein, this level of expression is difficult to
attain in other crops (Sala et al., 2003). Potato plants
transformed with a codon-optimized sLTB gene accumu-
lated 5- to 40-fold more LTB in the leaves than did lines
transformed with the unmodified LTB gene (Mason et al.,
1998). The eBRV4 peptide, which contains at least one
neutralizing epitope of the VP4 protein of bovine rotavirus
(BRV), was efficiently expressed in transgenic alfalfa as a
fusion protein with the stable reporter enzyme h-glucur-
onidase (h-GUS); the maximum expression level of
recombinant eBRV4-hGUS protein in transgenic lines
was 0.9 mg/g TSP. The eBRV4 epitope expressed in plants
was effective in inducing an anti-rotavirus antibody in adult
female mice, when administered either intraperitoneally or
orally. The suckling mice born from immunized female
mice were protected against oral challenge with virulent
rotavirus. (Wigdorovitz et al., 2004). Here, we showed that
the expression of sVP6 protein in transformed alfalfa
leaves was highly increased by using optimized codons, as
well as the 35S CaMV promoter, a Kozak sequence, the
TEV leader sequence, and the SEKDEL retention signal.
As shown in Fig. 4B, the expressed VP6 protein in the
leaves of transgenic alfalfa reached 33.04 Ag/g of fresh leaf
weight, or 0.28% of TSP, and successfully elicited the
production of serum IgG and mucosal IgA antibodies in
immunized mice.
Another limitation of the plant-based oral vaccines that
have been tested in clinical trials is the lack of a safe and
effective mucosal adjuvant for use in humans. The most
powerful mucosal adjuvants described to date are cholera
toxin (CT) and the closely related heat-labile enterotoxin
(LT) of E. coli; however, toxicity prevents their use in
humans. To avoid toxicity, the use of CT and LT mutants or
B subunits has been explored, but their activities as mucosal
adjuvants have proven to be much lower than those of the
respective holotoxins (Holmgren et al., 2003). A novel
mucosal adjuvant is composed of ODN containing immu-
nostimulatory CpG motifs. CpG ODN is an effective oral
adjuvant that can promote or enhance systemic and mucosal
immune responses to both weak (HBsAg) and strong
(tetanus toxoid) protein antigens (McCluskie et al., 2001).
The intranasal administration of CpG ODN together with
purified protein antigens promotes a mucosal Th2 response
with the formation of IgA and a systemic Th1 response.
Some reports have shown that the intranasal delivery of
CpG ODN induced responses stronger than those induced
by cholera toxin B subunit and equivalent to those induced
by CT (McCluskie et al., 2000). In this study, CpG ODN
was used for the first time as a mucosal adjuvant for an oral
vaccine derived from pBsVP6-transgenic alfalfa. The strong
immune responses elicited in immunized mice, including
high titers of anti-VP6 IgG and IgA, suggest that CpG ODN
is a safe and efficient mucosal adjuvant for oral vaccines.
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In conclusion, sVP6 protein was expressed at high levels
in transgenic alfalfa and successfully induced specific serum
IgG and mucosal IgA antibodies in mice. Passively immu-
nized mouse pups exhibited reduced diarrheal symptoms
compared with controls following challenge with simian
rotavirus SA-11. These results demonstrate that pBsVP6-
transgenic alfalfa is a candidate oral vaccine for the
protection of children and young animals against rotavirus
infection.Materials and methods
Modification of the coding sequence of the VP6 gene
To optimize the coding sequence for expression in
alfalfa, the 1194-nucleotide coding sequence of VP6
from the human rotavirus group A strain 97’B53
(GenBank accession no. AF260931) was analyzed, and
its codon usage was compared with the previously reported
codon usage of dicotyledonous plant genes (Perlak et al.,
1991). A number of codons in the VP6 coding sequence
were then modified to yield a sequence consistent with dicot
codon usage. We also modified a number of sequences that
can potentially destabilize mRNA, including potential
polyadenylation signal sequences (AATAAA, AATGAA,
AATAAT, AATATT, AATTAA, AATAAG, AACCAA,
GATAAA; located at nucleotide positions 46–51, 257–
262, 378–383, 509–514, 769–774, and 1015–1020),
mRNA destabilizing motifs (ATTTA; located at nucleotide
positions 99–103, 158–162, 369–373, and 693–697),
potential termination signals for RNA polymerase II
(AGTNNAA; located at nucleotide positions 780–786),
and plant RNA splice site consensus sequences. The AT
content of the modified gene was 56%, which accords with
the AT content in highly expressed dicot proteins. The
modified gene (sVP6) encoded an amino acid sequence
identical to that encoded by the original VP6 gene.
To optimize the expression of the protein in transgenic
plants, a plant translation initiation sequence (AAC-
CATGGCT) was added at the 5V end of the coding region.
A DNA sequence encoding the peptide SEKDEL (TCT
GAG AAA GAT GAG CTA) was ligated to the 3V end of the
modified gene to ensure retention of the expressed VP6
protein in the endoplasmic reticulum of the plant cell. The
modified synthetic gene was constructed into the pUC19
vector, forming the recombinant vector pUsVP6 (Shanghai
Sangon Company, Shanghai, China).
Analysis of sVP6 proteins expressed in E. coli
To examine expression in prokaryotic cells, the sVP6 and
VP6 genes were inserted into pGEX4T-1 at the BamHI and
XhoI sites, respectively, and the plasmids were transformedinto E. coli BL21. The expressed sVP6 and VP6 proteins
were purified by GST affinity chromatography, thrombin,
and FPLC. The purified VP6 proteins were used to
immunize rabbits for the production of polyclonal anti-
VP6 serum. Samples of the purified sVP6 and VP6 proteins
were incubated at 100 -C for 5 min in Laemmli loading
buffer (Laemmli, 1970) and analyzed by SDS-PAGE using a
10% resolving gel and a 4% stacking gel. The nondenatured
sVP6 and VP6 proteins were examined by incubating the
samples at 37 -C for 30 min without h-mercaptoethanol
before analysis by SDS-PAGE (O’Brien et al., 2000). The
separated proteins were transferred onto nitrocellulose
membranes for Western blotting using an Electro-transfer
unit (Bio-Rad, Hercules, CA, USA). After blocking with
phosphate-buffered saline (PBS) containing 0.05% Tween-
20 (PBST) and 5% skim milk for 3 h at 37 -C or overnight
at 4 -C, the membranes were reacted with rabbit anti-
rotavirus VP6 antibody (1:1,000), followed by alkaline
phosphatase-labeled goat anti-rabbit IgG (1:5,000) (Santa
Cruz Biotechnology, Santa Cruz, CA, USA). After washing,
the reaction was developed by the addition of nitroblue
tetrazolium/5-bromo-4-chloro-3-indolyl phosphate (NBT/
BCIP) substrate.
Construction of the plant expression vector
The sVP6 fragment including the 3V SEKDEL sequence
(1.2 kb) was cleaved from pUsVP6 using NcoI and SacI and
was ligated into the vector pRTL2 to yield pRsVP6, placing
the sVP6 gene downstream of the CaMV 35S promoter with
double enhancers to drive expression and the TEV 5V
untranslated region (5V-UTR) to mediate the enhancement of
translation initiation. The DNA fragment containing the 35S
promoter, the 5V-UTR, and the sVP6-SEKDEL sequence
was inserted into the binary plant vector pBI121 digested
with HindIII and SacI to produce the recombinant expres-
sion vector pBsVP6.
Plant transformation and regeneration
pBsVP6 was transformed into A. tumefaciens strain
LBA4404 by the freeze–thaw method, and the integrity of
the plasmids from LBA4404 was verified by PCR ampli-
fication, restriction digestion, and comparison with pBsVP6
from the parent E. coli DH5a cells. Alfalfa plants were
transformed using leaf disc co-cultivation with some
modifications (Desgagne´s et al., 1995). The alfalfa seeds
were grown in half-strength MS medium at 23 -C with a 16
h light and 8 h dark photoperiod. After 7 days, the
cotyledons and hypocotyls were sliced into pieces approx-
imately 3 cm in length and soaked in the A. tumefaciens
inoculum supplemented with 50 AM acetosyringone
(Aldrich, USA) for 15 to 30 min at room temperature.
After 4 days on callus medium without antibiotics, the plant
discs were thoroughly washed with sterile water, layered on
selection medium (SH medium supplemented with 2 Ag/ml
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250 Ag/ml of carbenicillin, and 25 Ag/ml of kanamycin), and
incubated for 2 to 3 weeks. The resistant calluses were
transferred to differentiation medium (SH medium supple-
mented with 0.4 Ag/ml of kinetin, 200 Ag/ml of carbeni-
cillin, and 25 Ag/ml of kanamycin) for embryonic
development and maturation. The plants were regenerated
on half-strength MS medium without hormones. Plants with
well-defined shoots and roots were transferred to vermic-
ulite and subsequently to soil.
Southern blotting and RT-PCR analysis of transformed
alfalfa
Genomic DNA was isolated from young leaves of
transformed and wild-type alfalfa plants using a plant
DNA extraction kit (TaKaRa Bio Inc., Japan), and aliquots
of each were digested with two restriction endonucleases
(SacI and HindIII) outside the sVP6 gene to show insertion
of gene into the plant genome. The pBsVP6 plasmid has
only one recognition site for each enzyme, permitting the
estimation of the complexity of the transgene copy
integration. The digested DNA samples were electrophor-
esed on 0.8% agarose gels and transferred onto Hybond N+
nylon membranes (Amersham Biosciences, USA.) for
hybridization. The probe was prepared from the 1.2-kb
sVP6 gene fragment by incorporation of a-32P dCTP using
a random-primer DNA labeling kit (Promega, Madison, WI,
USA). Standard protocols were used for Southern blot
analysis.
Total RNA was extracted from the leaves of transformed
and wild-type alfalfa plants using a plant RNA extraction kit
(TaKaRa). The expressed sVP6 mRNA was amplified by
RT-PCR from total RNA using an RT-PCR kit (TaKaRa)
with primers P1 (5V-ATG GAG GTT CTG TAC TCA TTG
TC-3V) and P2 (5V-AGA CTT GAT CAA CAT GCT TCT-
3V). The PCR products were separated by electrophoresis on
a 0.8% agarose gel and visualized under UV light after
staining with ethidium bromide.
Total soluble protein extraction and Western blot analysis
Alfalfa leaves were homogenized in liquid nitrogen with
a mortar and a pestle by the addition of an extraction buffer
containing 10 mM sodium phosphate buffer (pH 7.2, 105
mM NaCl, 0.05% Tween, 40 mM acid ascorbate, 20 mM
EDTA, and 1 mM PMSF). The total soluble protein was
precipitated with (NH4)2SO4 between 30% and 60%
saturation. The TSP was resuspended in PBS and dialyzed
before oral immunization or immunoassay.
For Western blot analysis, TSP samples were separated
by SDS-PAGE and transferred onto nitrocellulose mem-
branes using an Electro-transfer unit (Bio-Rad). The
membranes were sequentially incubated with rabbit poly-
clonal anti-VP6 antibody (1:1,000) and alkaline phospha-
tase-conjugated goat anti-rabbit IgG (1:5,000; Santa CruzBiotechnology), and the color reaction was developed as
described above for the proteins expressed in E. coli. To
determine the stability of the sVP6 gene in the transgenic
alfalfa, Western blotting was also used to analyze proteins
extracted from the T1 generation of the original transformed
lines.
ELISA quantification of sVP6 protein levels in transgenic
plants
A 96-well ELISA plate was coated with mouse anti-VP6
serum in carbonate buffer (pH 9.6) overnight at 4 -C. The
plate was washed three times with PBST and blocked with
3% BSA in PBST for 2 h at 37 -C. Aliquots of TSP extracts
from transgenic plants and samples of known amounts of
purified sVP6 protein (42 kDa) from recombinant E. coli
comprising a standard curve were added to the wells, and
the plate was incubated for 1 h at 37 -C. After three washes,
the plate was incubated with rabbit anti-VP6 serum
(1:1,000) for 1 h at 37 -C, followed by additional washes
and incubation with horseradish peroxidase-labeled goat
anti-rabbit IgG (1:5,000; Santa Cruz) for 1 h at 37 -C. The
reaction was developed by the addition of o-phenylenedi-
amine-H2O2 in citrate buffer (pH 5.0). The absorbance at
492 nm was measured using a microplate reader. The
expression of the sVP6 protein in the transgenic plants was
quantified by comparison with the standard curve.
Oral immunization of mice and antibody assay
Thirty female BALB/c mice (6–8 weeks old; Exper-
imental Animal Center, Peking Union Medical College,
Beijing, China) were divided into three groups and immu-
nized orally at weekly intervals for 4 weeks (days 0, 7, 14,
and 21) with the protein samples. CpG ODN 1826 (10 Ag)
was included as a mucosal adjuvant because it is a strong B
cell mitogen and a safe adjuvant for mucosal immunization
(McCluskie et al., 2001). The sequence of CpG ODN 1826
is TCC ATG ACG TTC CTG ACG TT, and it has a
phosphorothioate backbone.
The ten negative control mice in group 1 were gavaged
with 10 mg of TSP from untransformed alfalfa leaves and
CpG adjuvant. The ten mice in group 2 were gavaged with
10 mg of TSP from transgenic alfalfa, which contained 24
Ag of sVP6 protein from transgenic alfalfa, and CpG
adjuvant. The ten positive control mice in group 3 received
24 Ag of purified sVP6 from recombinant E. coli and CpG
adjuvant. Saliva and feces samples (homogenized in 0.01 M
PBS) were collected weekly from each animal for analysis
of anti-VP6 IgA. On day 36, serum samples were collected
and tested for IgG titers. On day 60, four mice in each group
were sacrificed, and the small intestines were collected and
homogenized in 0.01 M PBS for analysis of mucosal IgA.
The levels of anti-VP6 IgG and IgA were assayed by
ELISA using recombinant sVP6 protein as the antigen. A
96-well ELISA plate was coated with purified sVP6 protein
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was washed three times with PBST and blocked with 3%
BSA in PBST for 2 h at 37 -C. Blocking buffer were
discarded and diluted mouse serum (or saliva, homogenized
feces, homogenized small intestine) samples were added to
the wells, and the plate was incubated for 1 h at 37 -C. After
three washes, peroxidase-conjugated goat anti-mouse IgG
(Santa Cruz) or peroxidase-conjugated goat anti-mouse IgA
(Zymed, South San Francisco, CA) was used as the second
antibody to detect anti-VP6 IgG or IgA, respectively. The
reaction was developed by the addition of o-phenylenedi-
amine-H2O2 in citrate buffer (pH 5.0). Color development
was stopped by addition of an equal volume of 6 M H2SO4.
The antibody titers were expressed as the reciprocal of the
highest serum dilution yielding an OD492 that was at least
two-fold the mean OD492 for serum samples from the
negative controls.
SDS-PAGE and Western blot analysis were conducted to
confirm the specificity of the antibodies. Inactivated purified
rotavirus particles and purified sVP6 protein samples were
incubated at 100 -C for 5 min in Laemmli loading buffer
before loading on SDS-PAGE gels. The Western blot
analysis was performed as described above for the detection
of the sVP6 protein from E. coli, using the sera from the
immunized mice (1:50) as sample, and alkaline phospha-
tase-conjugated goat anti-mouse IgG as the second antibody
(Santa Cruz Biotechnology; Wigdorovitz et al., 2004).
Challenge experiments
The remaining immunized female mice were mated with
normal males on day 61 after the first immunization. Mouse
pups were born after a 19- to 20-day gestation period. On
the fifth day post parturition, pups were challenged using
the method of Yu and Langridge (2001). Each pup was
challenged with 20 DD50 of simian rotavirus strain SA-11.
The DD50 was the empirically determined viral dose that
induced diarrhea in 50% of native newborn mice. After SA-
11 virus challenge, the anus of each pup was checked three
times per day. The infected mice without watery feces
during the three-time check were classified as non-diarrheic
mice, otherwise classified as diarrheic mice. The intensity of
diarrhea was determined according to the color of anus and
the amount of adhered feces. The proportion of pups
showing diarrhea symptoms and the intensity of the diarrhea
symptoms were observed for at least 10 days after
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